Based on the Adaptive Biotechnologies Corporation stock forecast from 0 analysts, the average analyst target price for Adaptive Biotechnologies Corporation is not available over the next 12 months. Adaptive Biotechnologies Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adaptive Biotechnologies Corporation is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Adaptive Biotechnologies Corporation’s stock price was EUR 5.34. Adaptive Biotechnologies Corporation’s stock price has changed by +27.83% over the past week, +29.75% over the past month and +37.43% over the last year.
No recent analyst target price found for Adaptive Biotechnologies Corporation
No recent average analyst rating found for Adaptive Biotechnologies Corporation
Company Overview Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Read Less
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and mac...Read More
Frequently Asked Questions About Adaptive Biotechnologies Corporation (1HM:F) Stock
Stock Target Advisor's fundamental analysis for Adaptive Biotechnologies Corporation's stock is Bearish.
Unfortunately we do not have enough data on 1HM:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1HM:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 1HM:F's stock to indicate if its overvalued.
The last closing price of 1HM:F's stock was EUR 5.34.
The most recent market capitalization for 1HM:F is EUR 0.81B.
Unfortunately we do not have enough analyst data on 1HM:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adaptive Biotechnologies Corporation's stock.
As per our most recent records Adaptive Biotechnologies Corporation has 709 Employees.
Adaptive Biotechnologies Corporation's registered address is 1165 Eastlake Avenue East, Seattle, WA, United States, 98109.
You can get more information about it from Adaptive Biotechnologies Corporation's website at https://www.adaptivebiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Adaptive Biotechnologies Corporation (1HM:F) Stock
Stock Target Advisor's fundamental analysis for Adaptive Biotechnologies Corporation's stock is Bearish.
Unfortunately we do not have enough data on 1HM:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1HM:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 1HM:F's stock to indicate if its overvalued.
The last closing price of 1HM:F's stock was EUR 5.34.
The most recent market capitalization for 1HM:F is EUR 0.81B.
Unfortunately we do not have enough analyst data on 1HM:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adaptive Biotechnologies Corporation's stock.
As per our most recent records Adaptive Biotechnologies Corporation has 709 Employees.
Adaptive Biotechnologies Corporation's registered address is 1165 Eastlake Avenue East, Seattle, WA, United States, 98109.
You can get more information about it from Adaptive Biotechnologies Corporation's website at https://www.adaptivebiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 1HM:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
